<DOC>
	<DOCNO>NCT00094185</DOCNO>
	<brief_summary>To identify genetic variant 12 key blood clot protein may modify risk venous thromboembolism user hormone replacement therapy .</brief_summary>
	<brief_title>Clotting Genetic Variants , Hormones , Venous Thrombosis</brief_title>
	<detailed_description>BACKGROUND : Venous thromboembolism ( VTE ) occur commonly adult risk increase 3-fold among user hormone replacement therapy ( HRT ) , oral contraceptive ( OC ) , selective estrogen receptor modulators ( SERMs ) . Epidemiologic data suggest genetic variation pro-coagulant , anti-coagulant , fibrinolytic pathway may modify risk VTE woman , especially presence hormone use . The primary aim study identify genetic variant 12 key clot protein may modify risk VTE independently , gene-gene interaction , presence HRT , OC , SERM use . Proteins include thrombomodulin , protein C , endothelial protein C receptor , protein S , antithrombin III , tissue activatable fibrinolysis inhibitor ( TAFI ) , tissue plasminogen activator ( TPA ) , factor VIII , IX , X , XlII A B . Secondary aim determine level TAFI antigen , TPA antigen , activate protein C resistance , D-dimer serve intermediate phenotype gene-drug interaction VTE risk . The setting study Group Health Cooperative ( GHC ) Puget Sound , health maintenance organization Pacific Northwest . This study part go , case-control study address effect genetic variant drug safety , particularly cardiovascular endpoint . DESIGN NARRATIVE : The primary aim case-control study identify genetic variant 12 key blood clot protein may modify risk venous thromboembolism independently , gene-gene interaction , presence hormone replacement therapy , oral contraceptive , selective estrogen receptor modulators use . Proteins include thrombomodulin , protein C , endothelial protein C receptor , protein S , antithrombin III , tissue activatable fibrinolysis inhibitor ( TAFI ) , tissue plasminogen activator ( TPA ) , factor VIII , IX , X , XlII A B . Secondary aim study determine level TAFI antigen , TPA antigen , activate protein C resistance , D-dimer serve intermediate phenotype gene-drug interaction VTE risk . The setting study Group Health Cooperative ( GHC ) Puget Sound , health maintenance organization Pacific Northwest . This study part go , case-control study address effect genetic variant drug safety , particularly cardiovascular endpoint . All inpatient outpatient VTE event occur 1/1/1995 12/31/2007 among woman 18 89 year age eligible study . Controls random selection woman GHC match age , hypertension status , calendar year . Medical record review determine study eligibility collect V ' ' E risk factor information . Hormone SERM use ascertain GHC pharmacy database . Phlebotomy perform survive case control collect plasma sample genetic information . Logistic regression analysis determine haplotype key element clot pathway modify association hormone SERMSs VTE risk . The identification common genetic variant either increase decrease VTE risk independently presence hormone SERMs help inform clinician female patient personal safety hormone use . The Seattle Program Genomics Applications ( PGA ) identify single nucleotide polymorphism ( SNPs ) 12 candidate gene use linkage disequilibrium generate haplotype . A group Leiden University Medical Center perform genotyping study population .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<criteria>No eligibility criterion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>